Why India Is Falling Behind China — and What Must Change to Achieve Competitive Parity

India and China represent two of the most influential forces in global pharmaceuticals. India is globally recognized as the “Pharmacy of the World”, supplying affordable medicines at unmatched scale. China, however, has rapidly repositioned itself as an innovation-led pharmaceutical powerhouse.

Despite India’s manufacturing dominance, China is decisively pulling ahead in value creation, innovation depth, regulatory agility, and strategic control of supply chains. This divergence is not incidental—it is structural, policy-driven, and accelerating.

This blog outlines why the gap exists and how India can realistically move toward competitive parity—leveraging regulatory reform, quality intelligence, innovation enablement, and data-driven compliance frameworks.

From RIAR Consulting’s analysis, India’s competitive lag stems from four systemic gaps:

• Severe dependency on China for APIs and KSMs
• A widening innovation and R&D investment deficit
• Persistent regulatory quality and compliance perception risks
• Absence of a unified, long-term national pharmaceutical strategy

India’s pharmaceutical future cannot rely solely on volume leadership. The next phase demands innovation, regulatory excellence, supply-chain sovereignty, and data-driven decision-making.

1. Volume vs Value: The Core Structural Divide

India ranks 3rd globally by pharmaceutical volume, yet only 14th by value. China, in contrast, is 2nd globally by value, driven by biologics, patented therapies, and high-margin innovation.

While India’s pharmaceutical market is projected to grow at a healthy CAGR (8–11%), China’s growth—though slightly lower in percentage terms—adds far greater absolute value due to its innovation-heavy product mix.

2. API Dependency: India’s Strategic Choke Point

India imports 70–80% of its APIs and KSMs from China, including near-total dependence for critical molecules such as paracetamol, penicillin, ibuprofen, rifampicin, and amoxicillin.

This dependency creates:

• Geopolitical vulnerability
• Supply chain fragility
• Pricing exposure
• Regulatory continuity risks

China’s dominance is reinforced through:

• Massive economies of scale
• Vertical integration with chemical industries
• State subsidies and infrastructure support

India’s Production-Linked Incentive (PLI) schemes are a step forward—but remain defensive and corrective, not transformative.

3. The Innovation Gap: Where the Real Battle Is Lost

China invests ~2.4% of GDP in R&D. India invests <1% of GDP.

In absolute terms:

• China: ~USD 445 billion
• India: ~USD 28 billion

This gap directly translates into outcomes:

• 6 Chinese-origin innovative drugs approved by US FDA (2019–2024)
• 1 Indian-origin innovative drug approved in the same period

China’s success is amplified by:

• “Made in China 2025” & “Healthy China 2030”
• Fast-track regulatory approvals via NMPA
• Acceptance of global clinical trial data
• Strong IP protection for innovators
• Low cost of capital and deep biotech VC funding

India’s innovation ecosystem remains constrained by:

• High capital cost
• Risk-averse culture
• Limited academia–industry translation
• Brain drain of scientific talent

4. Regulatory Systems: Enabler vs Bottleneck

China (NMPA)

• Functions as a strategic accelerator
• Enables global trial data usage
• Offers priority and conditional approvals
• Actively attracts global R&D programs

India (CDSCO)

• Fragmented central–state processes
• Slower approval timelines
• Limited innovation-oriented pathways
• Reactive rather than enabling posture

Under US FDA inspections, India records a higher proportion of adverse outcomes, often related to cGMP deviations and quality system failures—impacting global confidence.

5. Global Expansion Strategies: Buying Markets vs Selling Innovation

Indian pharma expansion has largely focused on:

• Acquiring overseas generics portfolios
• Buying distribution and approvals
• Scaling existing business models

Chinese pharma expansion increasingly centers on:

• Licensing innovative assets globally
• Multi-billion-dollar biotech partnerships
• Exporting IP, not just products

This shift signals a fundamental repositioning of China as a global innovation supplier.

6. The China+1 Opportunity: India’s Strategic Opening

Global supply-chain diversification is real. India is well positioned to benefit—but only if it moves up the value chain.

To capitalize, India must demonstrate:

• Regulatory predictability
• Quality consistency
• API resilience
• Innovation readiness
• Data-driven compliance maturity

Low cost alone is no longer sufficient.

RIAR Consulting’s Strategic Roadmap for Competitive Parity

For Industry

• Transition from compliance checking to compliance intelligence
• Invest in predictive regulatory analytics
• Adopt AI-enabled quality systems
• Focus on niche innovation, not broad imitation

For Policymakers

• Create a unified long-term pharma innovation vision
• De-risk early-stage R&D via co-investment models
• Modernize CDSCO as a global innovation enabler
• Promote regulatory digitalization and transparency